Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Solid Tumors

Solid Tumors

Part of Cancer

29 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Solid Tumors

241 trials tracked for Solid Tumors: 7 in phase 3 or 4 and 3 with published results. The most-cited published study has 164 citations.

241Trials tracked
7Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 3 Phase 3 4 Phase 2 87 Phase 1 138 Other / NA 9
  1. Phase 3 QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas Completed · 164 cited
  2. Phase 4 Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection Completed · 16 cited
  3. Phase 4 Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy Completed · 6 cited
  4. Phase 4 Durvalumab Long-Term Safety and Efficacy Study Completed
  5. Phase 3 An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective Completed
  6. Phase 3 An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study Completed
Show 44 more trials
  1. Phase 3 Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Completed
  2. Phase 2 A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers Completed
  3. Phase 2 A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors Completed
  4. Phase 2 A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors Completed
  5. Phase 2 A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI Completed
  6. Phase 2 Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Completed
  7. Phase 2 Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies Completed
  8. Phase 2 A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Completed
  9. Phase 2 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed
  10. Phase 2 A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Completed
  11. Phase 2 Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors Completed
  12. Phase 2 Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer Completed
  13. Phase 2 Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors Completed
  14. Phase 2 A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) Completed
  15. Phase 2 Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part) Completed
  16. Phase 2 Pembrolizumab + Poly-ICLC in MRP Colon Cancer Completed
  17. Phase 2 An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols Completed
  18. Phase 2 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Completed
  19. Phase 2 Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Completed
  20. Phase 2 UCDCC#271: Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma Completed
  21. Phase 2 Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath Completed
  22. Phase 2 AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin Completed
  23. Phase 2 A Study to Assess the Potential Effects of a Single-Dose Administration of Trabectedin on the QT Intervals of the Electrocardiogram Completed
  24. Phase 2 Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Completed
  25. Phase 2 Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations Completed
  26. Phase 2 A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors Completed
  27. Phase 2 Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours Completed
  28. Phase 2 Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas Completed
  29. Phase 2 A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors Completed
  30. Phase 2 Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) Completed
  31. Phase 2 Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer Completed
  32. Phase 2 Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody Completed
  33. Phase 2 Study of Cabozantinib (XL184) in Adults With Advanced Malignancies Completed
  34. Phase 2 Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors Completed
  35. Phase 2 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors Completed
  36. Phase 2 Dexamethasone Dyspnea Study Completed
  37. Phase 2 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Completed
  38. Phase 2 Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers Completed
  39. Phase 2 Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC Completed
  40. Phase 2 Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors Completed
  41. Phase 2 Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies Completed
  42. Phase 2 Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath Completed
  43. Phase 2 Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials Completed
  44. Phase 2 Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors Completed

Showing the 50 most-cited and recently-updated of 241 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SMART radiation shows 90% 4-year local control in small oligometastatic abdominopelvic cohort
Urology Phase I
SMART radiation shows 90% 4-year local control in small oligometastatic abdominopelvic cohort Can targeted radiation safely treat small, recurring cancer spots in the abdomen?
A single-arm Phase 1/2 trial in 10 patients with solid tumor abdominopelvic oligometastases found Stereotactic MR-Guided Adaptive Radiation …
Targeted radiation safely controlled small recurring cancer spots in the abdomen for 90% of patients with only mild side effects after four …
Apr 3, 2026
Ifinatamab deruxtecan shows antitumor activity in advanced treatment-refractory solid tumors in phase 1/2 trial
Oncology Phase I
Ifinatamab deruxtecan shows antitumor activity in advanced treatment-refractory solid tumors in phase 1/2 trial Early trial shows experimental drug shrinks tumors in some patients with advanced cancers
This first-in-human phase 1/2 trial of 97 patients with advanced treatment-refractory solid tumors found a confirmed objective response rate…
An early trial of a new experimental drug shrank tumors in 34% of patients with advanced cancers that had stopped responding to standard tre…
Apr 3, 2026
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy
Oncology Phase II
CD8 PET imaging shows modest correlation with biopsy CD8 counts in solid tumor patients on immunotherapy New imaging method shows modest link to immune cell counts in solid tumors
A Phase II prospective multicenter study of 49 patients with solid tumors receiving immune checkpoint blockade found a modest correlation (c…
A new PET scan shows a modest link to immune cell counts inside solid tumors, with stronger results in kidney cancer patients.
Apr 2, 2026
Review describes biological barriers to CAR-T therapy in solid tumors and engineering strategies
Oncology Sys. Review
Review describes biological barriers to CAR-T therapy in solid tumors and engineering strategies Review explores challenges and potential solutions for CAR-T therapy in solid tumors
A systematic review synthesizing literature on CAR-T cell therapy for solid tumors found clinical efficacy remains modest and inconsistent d…
Solid tumors block CAR-T cells from reaching cancer, but new engineering strategies aim to overcome these barriers for better treatment.
Frontiers Apr 2, 2026
Comprehensive genomic profiling finds 0.2% NTRK fusion prevalence across solid tumors in community health system
Rheumatology Cohort
Comprehensive genomic profiling finds 0.2% NTRK fusion prevalence across solid tumors in community health system Study finds rare NTRK gene fusions in 0.2% of solid tumors in community health system
An observational cohort study of 15128 adult patients with solid tumors in a community health system found a 0.2% prevalence of pathogenic N…
Only 0.2% of solid tumors in a large community health system carry rare NTRK gene fusions, yet testing found eight new fusion types never de…
Frontiers Apr 2, 2026

Research across Cancer

Related studies from across the Cancer family.

FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
Oncology FDA Approval
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
FDA May 2, 2026
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
Narrative review discusses perioperative local anesthetics and regional anesthesia in cancer care
Drug Pipeline Sys. Review
Narrative review discusses perioperative local anesthetics and regional anesthesia in cancer care Local Anesthetics May Slow Cancer Spread
This narrative review examines the role of perioperative local anesthetics and regional anesthesia compared to opioids within comprehensive …
Using local anesthesia instead of just opioids during surgery might help stop cancer from spreading after the operation.
Frontiers Apr 24, 2026
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors
Oncology Phase I
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors Could a simple injection replace hours-long cancer infusions?
A phase Ib clinical trial in 158 patients with advanced solid malignancies evaluated subcutaneous amivantamab administration.
A new injection method for advanced cancer treatment cuts administration time to under 10 minutes and reduces severe side effects compared t…
Apr 6, 2026

Questions about Solid Tumors

How many patients with advanced solid tumors received immune checkpoint inhibitors in the study?

The meta-analysis included 6,129 patients with advanced solid tumors who received immune checkpoint inhibitors across 29 studies.

Full answer →
How might adapter-based CAR T cells be used to treat solid tumors effectively?

Adapter-based CAR T cells use small-molecule adapters to target multiple tumor antigens, helping overcome antigen escape and improving effectiveness against solid tumors.

Full answer →
What are the main challenges facing NK cell immunotherapy for treating solid tumors?

NK cell immunotherapy for solid tumors faces major hurdles: poor tumor infiltration, the immunosuppressive tumor microenvironment, antigen heterogeneity, and limited persistence of NK cells.

Full answer →